Ensysce Biosciences (ENSC) received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent covering additional opioid families, utilizing the Company’s proprietary TAAP and MPAR technologies. The newly allowed patent includes both composition of matter and method of use claims, further strengthening Ensysce’s intellectual property estate and expanding its global protection for Next Generation analgesics. This patent builds on the protection Ensysce has around additional opioid families not only in North America but also in the EU and South America.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC:
- Ensysce Biosciences Shareholders Approve Key Corporate Actions
- Ensysce Biosciences receives EU patent for ADHD therapy
- Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch
- Ensysce Biosciences CEO says ‘positioned for continued momentum’
- Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614